Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bispecific antibodies for immune cell retargeting against cancer

29 Apr 2022

Abstract excerpt

INTRODUCTION: Following the approval of the T cell engaging bispecific antibody blinatumomab, immune cell retargeting with bispecific or multispecific antibodies has emerged as a promising cancer immunotherapy strategy, offering alternative mechanisms compared to immune checkpoint blockade. As we gain more understanding of the complex tumor microenvironment, rules and design principles have started to take shape...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35485219
DOI: 10.1080/14712598.2022.2072209

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 21 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bispecific antibodies for immune cell retargeting against cancerPMID 35485219Read ↗

Principles and Current Clinical Landscape of Multispecific Antibodies against CancerSemantic proximity Read ↗

Targeting cancer with bispecific antibodies.Semantic proximity Read ↗

A computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of actionSemantic proximity Read ↗

Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagersSemantic proximity Read ↗

Mechanism of Action and Pharmacokinetics of Approved Bispecific AntibodiesSemantic proximity Read ↗

P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapy.Semantic proximity Read ↗

The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagersSemantic proximity Read ↗

AI-Guided CAR Designs and AKT3 Degradation Synergize to Enhance Bispecific and Trispecific CAR-T Cell Persistence and Overcome Antigen EscapeSemantic proximity Read ↗

From molecular design to clinical translation: dual-targeted CAR-T strategies in cancer immunotherapySemantic proximity Read ↗

The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomasSemantic proximity Read ↗

Development of T-cell engagers selective for cells co-expressing two antigensSemantic proximity Read ↗

A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.